MAPK Signaling - Acute Myeloid Leukemia - Cervical Cancer - Cancer
The mitogen-activated protein kinase (MAPK) is a highly conserved family of serine/threonine kinases that mediate a board range of cellular processes, including proliferation, differentiation, motility, migration, stress response, apoptosis and survival. The activation of MAPK involves signaling pathways consisting of MAPK kinase (i.e. MAPKKK or MEKK) that activates MAPK/ERK (i.e. MAPKK or MEK). A variety of extracellular signals such as mitogens, cytokines, growth factors, and environmental stressors stimulate a phosphorylation-dependent increase in the activity of MAPK.
Activated MAPKs transduce the phosphorylation and activation of MAPK-activated protein kinases (MAPKAPKs), e.g. RSK, MSK, or MNK family, and MK2/3/5. There are three main MAPK families, signal-regulated kinase 1 and 2 (Erk1/2 or p44/42), the c-Jun N-terminal kinases 1-3 (JNK1-3)/ stress activated protein kinases (SAPK1A, 1B, 1C), the p38 isoforms (p38α, β, γ, and δ). ERK signaling is involved in cell division, migration and survival. p38 MAPK and JNK/SAPK pathways are activated by cellular stress. The p38 MAPK pathway regulates cell motility, transcription, and chromatin remodeling. JNK/SAPK signaling affects apoptosis and inflammation. Dysregulation of MAPK pathway results in tumorgenesis and other pathological conditions.
清除全部
- B6012 Pexmetinib (ARRY-614)Target: p38|Tie-2Summary: p38 MAPK 和 Tie2/Tek 受体酪氨酸激酶的双重抑制剂
- A8716 LY3009120Target: RafSummary: Pan-RAF和RAF二聚体抑制剂
- B6962 CMPD-1Target: Microtubules/Tubulins|MK2Summary: p38α介导的MK2a磷酸化的抑制剂
- B1135 GDC-0623Target: MEKSummary: MEK1抑制剂
- B1267 RefametinibTarget: MEKSummary: MEK1/MEK2抑制剂
- B1621 TAK-733Target: MEKSummary: MEK变构位点抑制剂
- A8374 AZD8330Target: MEKSummary: MEK 1/2抑制剂
- A8313 RAF265Target: Raf|VEGFRSummary: 多细胞激酶抑制剂
- A8304 FR 180204Target: ERKSummary: ERK inhibitor
- A1947 MEK162 (ARRY-162, ARRY-438162)中文名: 贝美替尼Target: MEKSummary: MEK1/2抑制剂